Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Pancrelipase Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedAmbetter NevadaPolicy CP.PCH.44

    Clinical Policy: Pancrelipase (Creon, Pancreaze, Pertzye, Viokace, Zenpep)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PCH.44 alerts

    Get alerted when Policy CP.PCH.44 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs commercial-plan coverage and prior authorization for pancrelipase products when documented clinical, step-therapy, product-specific, and dosing criteria are met for exocrine pancreatic insufficiency.

    Policy Summary
    PayerAmbetter Nevada
    PolicyPancrelipase coverage and prior authorization
    Policy CodePolicy CP.PCH.44
    Change TypeModified
    Effective DateMar 1, 2022
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionFor Commercial requests for Pertzye or Viokace, document failure of Pancreaze, Creon, and Zenpep.
    SourceLink
    POLICY UPDATE CHANGES

    The maximum dose criterion was revised to include 10,000 lipase units per kilogram per day in accordance with prescribing information.

    Commercial requests for Pertzye or Viokace now require failure of Pancreaze, Creon, and Zenpep.

    Pancreaze requests are now subject to redirection to Creon and Zenpep.

    Examples of positive response for continuation therapy were added, including reduced steatorrhea and gastrointestinal symptoms, gains in weight or muscle measures, and improved fat-soluble vitamin levels.

    5 productsProducts covered
    Exocrine pancreatic insufficiencyCovered condition
    2,500 units/kg

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum meal dose
    10,000 units/kg/dayMaximum daily dose
    3Required preceding products

    Coverage Criteria

    Initial therapy — pancreatic insufficiency

    Covered for pancreatic insufficiency when all criteria are met.

    Initial pancreatic insufficiency criteria

    • Diagnosis: Member has a diagnosis of exocrine pancreatic insufficiency, such as insufficiency due to cystic fibrosis, chronic pancreatitis, or pancreatectomy.
    • Product-specific step therapy or exception

      • HIM and California Exchange Plans: For a request for Pancreaze, Pertzye, or Viokace, the member has failed Creon and Zenpep.
      • Commercial Plans: For a request for Pertzye or Viokace, the member has failed Pancreaze, Creon, and Zenpep.
      • Step-therapy exception: Clinically significant adverse effects were experienced with the required alternatives, or all required alternatives are contraindicated.
    • Viokace-specific criteria: If the request is for Viokace, the member is at least 18 years old and Viokace is prescribed concurrently with a proton pump inhibitor.Age ≥ 18 years

      Applies only to Viokace requests.

    • Dose limit

      • The dose does not exceed 2,500 lipase units/kg per meal.2,500 lipase units/kg per meal
      • The dose does not exceed 10,000 lipase units/kg per day.10,000 lipase units/kg per day
      • The dose does not exceed 4,000 lipase units/g of fat ingested per day.4,000 lipase units/g of fat ingested per day

    Continuation therapy — pancreatic insufficiency

    Continuation is covered when all criteria are met.

    Continuation pancreatic insufficiency criteria

    • Existing therapy or continuity of care

      • The member is currently receiving the medication through the Centene benefit or previously met the initial approval criteria.
      • The member is currently receiving the medication and is enrolled in a state and product subject to continuity-of-care regulations.

        Refer to applicable state-specific continuity-of-care addenda when relevant.

    • Positive response: The member is responding positively to therapy, such as through reduced steatorrhea or gastrointestinal symptoms, weight or muscle gain, improved muscle function, or improved fat-soluble vitamin levels.

      Examples are not exhaustive.

    Other diagnoses and indications

    Other diagnoses or indications must meet one of the following policy pathways.

    Other diagnoses or indications

    • Recent label change pathway: If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy, refer to the applicable no-coverage-criteria or non-formulary policy for the relevant line of business.Recent label change within the last 6 months

      For Commercial Plans, refer to CP.CPA.190. For HIM/ICHRA, refer to HIM.PA.33 for formulary or PDL drugs or HIM.PA.103 for non-formulary drugs.

    • Off-label use pathway: If the requested use, including the diagnosis, age, or dosing regimen, is not specifically listed under the policy's unauthorized indications and the recent-label-change pathway does not apply, refer to the applicable off-label use policy.

      For Commercial Plans, refer to CP.CPA.09. For HIM/ICHRA, refer to HIM.PA.154.

    Continuation therapy positive response

    Continuation therapy requires evidence of a positive clinical response; examples are not exhaustive.

    Positive response

    • Clinical response: Reduction in steatorrhea and associated gastrointestinal symptoms.
    • Nutritional or muscle improvement: Gain of weight, muscle mass, or muscle function.
    • Vitamin improvement: Improvement in fat-soluble vitamin levels.

    Non-FDA-approved indications that are not addressed in this policy are not authorized for coverage unless sufficient documentation of efficacy and safety supports review under the applicable off-label use policy or evidence of coverage documents.

    Dose and Quantity Parameters

    Maximum lipase dose per meal
    Maximum per meal2,500 lipase units/kg per meal
    Measurement basisLipase units per kilogram of body weight
    ApplicationThe limit applies to the requested dose, including dose increases during continued therapy
    Maximum daily lipase dose by body weight
    Maximum daily dose by body weight10,000 lipase units/kg per day
    Measurement basisLipase units per kilogram of body weight per day
    ApplicationThe limit applies to the requested dose, including dose increases during continued therapy

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Prior Authorization

    Prior authorization is required for initial requests. Submit office chart notes, laboratory results, or other clinical information demonstrating that the member meets all applicable initial approval criteria for the requested pancrelipase product.

    • Document exocrine pancreatic insufficiency and its underlying cause, such as cystic fibrosis, chronic pancreatitis, or pancreatectomy.
    • Document applicable prerequisite-product failures, Viokace age and proton-pump-inhibitor requirements, and dosing within policy limits.
    Denial Risk

    Failure to Meet Initial Approval Criteria

    An initial request may be denied when the member does not meet every applicable approval criterion.

    • No documented diagnosis of exocrine pancreatic insufficiency or underlying cause.

    Clinical Background

    Pancrelipase is a porcine-derived combination of lipases, proteases, and amylases used to replace pancreatic digestive enzymes. The policy includes Creon, Pancreaze, Pertzye, and Zenpep for exocrine pancreatic insufficiency in adults and children. Viokace is covered for adults with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy and must be used concurrently with a proton pump inhibitor.

    Definitions

    Pancrelipase
    SourcePorcine-derived digestive enzyme combination
    Lipase componentLipases
    Other enzyme componentsProteases and amylases
    Exocrine pancreatic insufficiency
    ConditionExocrine pancreatic insufficiency
    Underlying problemInadequate pancreatic digestive enzyme secretion
    Clinical effectImpaired digestion and absorption

    Initial Therapy Criteria

    Pancrelipase initial therapy

    Initial therapy requires all applicable criteria below.

    • Exocrine pancreatic insufficiency: The member has a diagnosis of exocrine pancreatic insufficiency, such as insufficiency due to cystic fibrosis, chronic pancreatitis, or pancreatectomy.
    • Applicable step therapy or exception

      • HIM and California Exchange Plans: For a request for Pancreaze, Pertzye, or Viokace, the member has failed Creon and Zenpep.
      • Commercial Plans: For a request for Pertzye or Viokace, the member has failed Pancreaze, Creon, and Zenpep.

    Continuation Criteria

    Pancrelipase continuation therapy

    Continuation requires all criteria below.

    • Prior qualifying therapy or continuity of care

      • The member is currently receiving the medication through the Centene benefit or previously met the initial approval criteria.
      • The member is currently receiving the medication and is enrolled in a state and product subject to continuity-of-care regulations.

        Refer to applicable state-specific continuity-of-care addenda when relevant.

    • Positive response: The member is responding positively to therapy, including outcomes such as reduced steatorrhea or associated gastrointestinal symptoms, gain of weight or muscle mass and function, or improved fat-soluble vitamin levels.

      Examples are not exhaustive.

    Step Therapy Requirements

    Plan / requested productRequired prior therapyException
    Commercial Plans — Pertzye or ViokaceFailure of Pancreaze, Creon, and ZenpepRequirement does not apply when clinically significant adverse effects occur or all alternatives are contraindicated.
    Plan / requested productRequired prior therapyException
    HIM and California Exchange Plans — Pancreaze, Pertzye, or ViokaceFailure of Creon and ZenpepRequirement does not apply when clinically significant adverse effects occur or all alternatives are contraindicated.
    Requested productRequired prerequisite failures
    Pertzye or Viokace — Commercial PlansPancreaze, Creon, and Zenpep
    Requested productPreferred alternatives / redirection
    PancreazeRedirect to Creon and Zenpep

    Quantity Limits

    Per-meal quantity limit
    Covered productsCreon, Pancreaze, Pertzye, Viokace, or Zenpep
    Per-meal quantity limit2,500 lipase units/kg per meal
    Limit typeMeal-based maximum
    Daily weight-based quantity limit
    Covered productsCreon, Pancreaze, Pertzye, Viokace, or Zenpep
    Daily quantity limit by body weight10,000 lipase units/kg per day
    Limit typeDaily weight-based maximum
    Policy Summary
    PayerAmbetter Nevada
    PolicyPancrelipase coverage and prior authorization
    Policy CodePolicy CP.PCH.44
    Change TypeModified
    Effective DateMar 1, 2022
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionFor Commercial requests for Pertzye or Viokace, document failure of Pancreaze, Creon, and Zenpep.
    SourceLink
    On This Page
    Coverage CriteriaDose and Quantity ParametersAuthorization and Documentation RequirementsClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy RequirementsQuantity Limits
    Dose increase limit: If a dose increase is requested, the new dose does not exceed the applicable maximum dose threshold.2,500 lipase units/kg per meal; 10,000 lipase units/kg per day; or 4,000 lipase units/g of fat ingested per day
    Maximum daily lipase dose by dietary fat
    Maximum daily dose by dietary fat4,000 lipase units/g of fat ingested per day
    Measurement basisLipase units per gram of fat ingested
    ApplicationThe limit applies to the requested dose, including dose increases during continued therapy
    Maximum daily lipase dose
    Revised maximum daily dose10,000 lipase units/kg/day
    Policy basisThe maximum dose criterion was revised to include 10,000 lipase units/kg per day in accordance with prescribing information
    Clinical useThis is a clinical dosing limitation used in coverage criteria
  1. Required prerequisite-product failures, Viokace requirements, or dose limits are not satisfied.
  2. For Illinois HIM requests, the stated step-therapy requirements do not apply as of January 1, 2026, per IL HB 5395.
  3. Prior Authorization

    Continuation Prior Authorization

    Continuation authorization is required for ongoing therapy. Document eligibility for continued treatment, positive response, and any applicable dose change. Approval is generally for 12 months for HIM/ICHRA and 12 months or the requested duration, whichever is less, for Commercial plans.

    • The member must be receiving the medication through the Centene benefit, have previously met initial criteria, or qualify under applicable state and product continuity-of-care regulations.
    • For dose increases, document that the new dose remains within the policy limits.
    Denial Risk

    Failure to Meet Continuation Criteria

    A continuation request may be denied when continuity, response, or dose requirements are not documented.

    • The member does not meet a qualifying current-therapy or continuity-of-care pathway.
    • There is no documented positive response to treatment.
    • A requested dose increase exceeds a policy limit.

    Unsupported block type: documentation

    Step Therapy

    Pancreaze Preferred Alternatives

    For Pancreaze requests under HIM and California Exchange Plans, redirect the member to preferred alternatives unless clinically significant adverse effects are experienced or all alternatives are contraindicated.

    • Document failure of both Creon and Zenpep, or the applicable exception.
    • This redirection applies to HIM and California Exchange Plans.
    Step Therapy

    Commercial Step Therapy

    For Commercial requests for Pertzye or Viokace, document failure of the required preferred pancrelipase products before requesting the nonpreferred product.

    • Required Commercial prerequisites: Pancreaze, Creon, and Zenpep.
    • The step requirement may be bypassed when clinically significant adverse effects are experienced or all required alternatives are contraindicated.
    Step Therapy

    HIM and California Exchange Step Therapy

    Step-therapy requirements differ by plan and product. Submit documentation addressing the applicable plan-specific prerequisite therapy.

    • HIM and California Exchange requests for Pancreaze, Pertzye, or Viokace require failure of Creon and Zenpep, unless clinically significant adverse effects are experienced or all are contraindicated.
    • For Illinois HIM requests, these step-therapy requirements do not apply as of January 1, 2026, per IL HB 5395.
    Step Therapy

    Pertzye and Viokace Prerequisite Therapy

    Before requesting Pertzye or Viokace under a Commercial plan, document failure of all three required prerequisites.

    • Required failures: Pancreaze, Creon, and Zenpep.
    • Document clinically significant adverse effects or contraindications when relying on an exception to step therapy.
    Step Therapy

    Pancreaze Redirection

    For Pancreaze requests under HIM and California Exchange Plans, direct treatment to Creon and Zenpep unless the required alternatives have failed or cannot be used.

    • Document failure of Creon and Zenpep.
    • Document clinically significant adverse effects or contraindications supporting an exception.
    Documentation Required

    Clinical Documentation

    Submit clinical documentation sufficient to establish medical necessity and the member's satisfaction of all applicable criteria.

    • Office chart notes, laboratory results, and other clinical information are acceptable supporting records.
    • Records should support the diagnosis, treatment history, response, product-specific requirements, and prescribed dose.
    Documentation Required

    Initial Request Support

    For an initial request, document exocrine pancreatic insufficiency, its underlying cause, and relevant treatment history.

    • Acceptable examples of underlying causes include cystic fibrosis, chronic pancreatitis, and pancreatectomy.
    • Include prior pancrelipase products, outcomes, adverse effects, and contraindications when prerequisite therapy applies.
    Documentation Required

    Continuation Request Support

    For continuation requests, document current therapy and clinical response, including any requested dose change.

    • Show that the member is currently receiving the medication through the Centene benefit, previously met initial criteria, or qualifies under continuity-of-care regulations.
    • If requesting a dose increase, provide the current and proposed doses and demonstrate that the new dose remains within limits.
    Documentation Required

    Document Preferred-Product Failures

    When Commercial step therapy applies, the record must document failure of each required preferred product before Pertzye or Viokace is approved.

    • Document failure of Pancreaze, Creon, and Zenpep.
    • If a prerequisite was not tried, document clinically significant adverse effects or a contraindication to support an exception.
    Documentation Required

    Document Clinical Response

    Document a positive clinical response to support continuation of pancrelipase therapy.

    • Examples include reduced steatorrhea and associated gastrointestinal symptoms.
    • Other examples include gain of weight, muscle mass, and muscle function, or improvement in fat-soluble vitamin levels.
    Denial Risk

    Initial Approval Denial Risk

    Initial approval is at risk of denial when the submitted records do not establish exocrine pancreatic insufficiency, applicable prerequisite-product requirements, product-specific requirements, or an allowable dose.

    • For Viokace, the member must be at least 18 years old and use Viokace concurrently with a proton-pump inhibitor.
    • The prescribed dose must not exceed 2,500 lipase units/kg per meal, 10,000 lipase units/kg per day, or 4,000 lipase units/g of fat ingested per day.
    Denial Risk

    Non-FDA-Approved Indication

    Coverage is not authorized for non-FDA-approved indications addressed by neither this policy nor an applicable exception pathway.

    • An exception may be considered with sufficient documentation of efficacy and safety under CP.CPA.09 for Commercial plans, HIM.PA.154 for health insurance marketplace/ICHRA plans, or the applicable evidence of coverage document.
    Denial Risk

    Continuation Approval Denial Risk

    Continuation approval is at risk of denial when the member's qualifying therapy status, positive response, or dose requirements are not documented.

    • Document current treatment through the Centene benefit, prior satisfaction of initial criteria, or applicable continuity-of-care eligibility.
    • Document positive response, such as reduced steatorrhea or gastrointestinal symptoms, improved nutritional status, or weight and muscle gains.
    • Any dose increase must remain within the policy limits.
    Denial Risk

    Required Preferred-Product Failures

    A Commercial request for Pertzye or Viokace is at risk of denial when failure of required preferred products is not documented.

    • Document failure of Pancreaze, Creon, and Zenpep.
    • If clinically significant adverse effects or contraindications prevent prerequisite use, document the applicable exception.
    Denial Risk

    Pancreaze Redirection Risk

    Pancreaze requests under HIM and California Exchange Plans may be redirected to Creon and Zenpep unless the record supports an exception.

    • Document failure of both Creon and Zenpep.
    • Document clinically significant adverse effects or contraindications when requesting an exception to redirection.
    Denial Risk

    Maximum Daily Dose

    Requests for doses above 10,000 lipase units/kg/day are at risk of denial or limitation because the policy maximum is exceeded.

    • The dose must also not exceed 2,500 lipase units/kg per meal or 4,000 lipase units/g of fat ingested per day.
    • The same limits apply when requesting a continuation dose increase.
    Exception: Clinically significant adverse effects were experienced with the required alternatives, or all required alternatives are contraindicated.
  4. Viokace requirements: If the request is for Viokace, the member is at least 18 years old and Viokace is prescribed concurrently with a proton pump inhibitor.Age ≥ 18 years

    Applies only to Viokace requests.

  5. Dose limit

    • Dose does not exceed 2,500 lipase units/kg per meal.2,500 lipase units/kg per meal
    • Dose does not exceed 10,000 lipase units/kg per day.10,000 lipase units/kg per day
    • Dose does not exceed 4,000 lipase units/g of fat ingested per day.4,000 lipase units/g of fat ingested per day
  6. Dose increase limit: If a dose increase is requested, the new dose does not exceed the applicable maximum dose threshold.2,500 lipase units/kg per meal; 10,000 lipase units/kg per day; or 4,000 lipase units/g of fat ingested per day

    Positive response for continuation

    Continuation therapy requires evidence of a positive response; examples are not limited to the outcomes listed below.

    Positive response

    • Gastrointestinal improvement: Reduction in steatorrhea and associated gastrointestinal symptoms.
    • Weight or muscle improvement: Gain of weight, muscle mass, or muscle function.
    • Vitamin improvement: Improvement in fat-soluble vitamin levels.
    Dietary-fat-based quantity limit
    Covered productsCreon, Pancreaze, Pertzye, Viokace, or Zenpep
    Daily quantity limit by dietary fat4,000 lipase units/g of fat ingested per day
    Limit typeDaily dietary-fat-based maximum